Cardiologist, drug developer, board member AnaptysBio, recovering professor of medicine, science enthusiast, author, amateur rock critic, father, husband.
The CVS analysis shows these medicines reduce hospital stays 34-42%, ER visits 10-12%, and major heart event odds 14%. That is the news.
On price: the $617-766 employer figure is dated. Employers can now get Zepbound KwikPen for $449 a month (less employee out-of-pocket) at every dose; Foundayo is even lower. Medicare and Medicaid pay $245. U.S. realized prices fell 15% in Q3 2025 and another 7% in Q3 2026.
Three years is a short window for a chronic disease; modeling shows compounding benefits over time. Greater access in employer insurance markets could cut health costs and deliver broader human and economic gains. We agree with CVS: broaden coverage for Americans.
Proud to build in Pennsylvania and build in America! Governor your team is terrific and we are excited to get this hi-tech plant built, hire 850 Lehigh Valley residents and make medicine for the world. The innovative medicines from our labs are amazing but will only have impact when they reach the people who need them. That starts with building capacity here in America. Let’s go!!🇺🇸🇺🇸🇺🇸
I think that would be amazing and I think it’s not likely. The map of biology is still largely a blank page and randomized human proof is the long pole in the tent. I am excited about the use of AI in our sector but progress will likely be steady and incremental.
Dissent is obviously key to the scientific process, I often worry about herd mentality in decision processes we have, but I suspect its much worse in academic medicine because reputation and hierarchy are the currency of the realm. That said this industry is really hard because differentiating between good ideas that just need more work (better drug, better experiment ala Amyloid Beta ) and bad ideas that should be dropped (dead end biologic target that is drugged well enough ala CETPi) is non obvious much of the time, until it isn’t. Too often after a ton of money and time invested in human CTs. So just listening to the dissenters isn’t good enough and neither is over simplified pattern recognition across biology - designing POCs that really test the idea much better.
Convincingly negative result here. IL6 looks almost the same. Not often 2 of the most anticipated targets in CV go down at once. There will be lots of Monday morning quarterbacking these bets but it’s why we do the studies and they were reasoned bets, uncertain outcomes despite genetics and biomarkers with asymmetric value if positive. Drug development isn’t rocket science, its actually much harder.
In the near term, beyond LDL optimization (looks like real benefit), Incretin therapy in obesity now the one big idea left on the board to reduce CVD death and disability at scale. Surmount MMO is coming! https://t.co/cgceDo74rW
Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a) | New England Journal of Medicine https://t.co/kWfyy3jKef
Tonight, I make a solemn promise to every single Texan. Whether you voted for me or Governor Abbott, or felt so betrayed by a broken politics that you did not vote at all.
Hear what Texas said today, loud and clear: Your government belongs to you. And as your governor, I will never forget it. There will be no special set of rules for the wealthy and powerful. No looking the other way when someone in my own party does wrong.
The trust you have placed in me tonight is not a blank check. It is a sacred responsibility. And I intend to earn it every single day.
It’s difficult to create a campaign ad so inspirational, that talks about the future, that makes people patriotic, without tearing anyone down. Here’s the new ad for Texas Senate candidate @JamesTalarico. His opponent Paxton couldn’t do something with this much heart in 100 yrs.
Well I should have added a few more critical questions to this list
-Peer reviewed and presented at a medical meeting or published in a journal >>> pre print + press release while a meeting is going on
- For post hoc or RWE publish your methods and caveats, your sample and absolute event rates and measures - better to have it verified by independent group - real science is transparent and can be replicated.
EASD in 2 weeks! A lot of weight-loss numbers are about to drop..including 3 major studies from @EliLillyandCo.
Before we understand a molecule’s performance we need to understand design choices that move a topline weight loss number:
- Baseline & mix. BMI, diabetes status, sex and ethnicity all shift observed response
-Stats methods. Treatment-policy and efficacy estimands answer different questions and trial drop out matters for real world outcomes. Mixing them is not appropriate.
- Uncontrolled tails. Open-label extensions and crossovers can keep weight falling after randomization ends. That is not a new efficacy estimate.
- Execution. Lifestyle intensity, titration schedule, time at maintenance dose, and placebo-arm drop-in of approved medicines (important new trend..see ADA survo data).
Head-to-head data settle all this and should be much more widely used in the future. Where they don't exist, an indirect comparison is one data point — anchored, covariate-adjusted, prespecified, assumptions stated.
Those rules apply to our work too. Hold us to them.
Methods first. Then the number.
Ignore the lack of brevity, but Mark is about the only household name that understands what's driving the excesses of the US health care system
He's 100% correct here:
"It did my heart some good to see an 81 year old Robin Trower bring the house down with a Strat and 2 Marshalls tonight.
It was loud.
It was glorious"
Chris Blackwell, Producer. The US tour continues this week, new album 'Shine' out Friday!
@ethanjweiss Agree with those 3 possibilities. Also possible that the majority of risk is in the far tail of lp(a) distribution and those with less severe elevations diluted the signal.